Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study
Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study
复制标题
DOI：
10.1093/cdn/nzaa095
复制
发表时间：
2020-07-01
影响因子：
4.8
通讯作者：
Petersen, Andreas Munk
中科院分区：
文献类型：
--
作者：
Halkjaer, Sofie Ingdam;de Knegt, Victoria Elizabeth;Petersen, Andreas Munk
背景：母亲肥胖与不良妊娠结局相关。怀孕期间补充益生菌可能对血糖、妊娠期体重增加（GWG）和妊娠期糖尿病风险[GDM和糖化血红蛋白（HbA 1c）]产生积极影响。目的：这项可行性研究涉及肥胖孕妇从孕中早期到分娩的每日益生菌干预。主要目的是研究对GWG和母体葡萄糖稳态（GDM和HbA 1c）的影响。次要目的是对婴儿出生体重，产妇肠道菌群，和其他妊娠outcome.Methods的影响：我们进行了一项随机双盲安慰剂对照研究，在50名肥胖孕妇。参与者在妊娠14-20周时被随机分配（1：1）到多菌株益生菌（4粒Vivomixx（R）胶囊;总计4500亿CFU/d）或安慰剂组，直至分娩。参与者在妊娠第27-30周和第36-37周进行了2次产前访视，并进行了1次产后访视。所有访视均包括血液和粪便采样。在入选时和妊娠27- 30周进行口服葡萄糖耐量试验。结果：49名参与者完成了研究。38名参与者服用了>80%的胶囊（n = 21），安慰剂（n = 17）。两组间GWG、GDM、HbA 1c浓度和婴儿出生体重无显著差异。粪便微生物群分析显示，随着时间的推移，仅益生菌组的α-多样性总体增加（P = 0.016）。结论：妊娠期间给予益生菌对肥胖妇女是可行的，并且妇女愿意参加额外的研究访问和妊娠期间粪便样本的收集。多菌株益生菌可以调节怀孕期间肥胖妇女的肠道微生物群。需要更大的研究人群来揭示益生菌补充剂对妊娠的影响。
Background: Maternal obesity is associated with adverse pregnancy outcomes. Probiotic supplementation during pregnancy may have positive effects on blood glucose, gestational weight gain (GWG), and the risk of gestational diabetes mellitus [GDM and glycated hemoglobin (HbA1c)].Objectives: This feasibility study involved a daily probiotic intervention in obese pregnant women from the early second trimester until delivery. The primary aim was to investigate the effect on GWG and maternal glucose homeostasis (GDM and HbA1c). Secondary aims were the effect on infant birth weight, maternal gut microbiota, and other pregnancy outcomes.Methods: We carried out a randomized double-blinded placebo-controlled study in 50 obese pregnant women. Participants were randomly allocated (1:1) to multistrain probiotic (4 capsules of Vivomixx (R); total of 450 billion CFU/d) or placebo at 14-20 weeks of gestation until delivery. Participants were followed with 2 predelivery visits at gestational week 27-30 and 36-37 and with 1 postdelivery visit. All visits included blood and fecal sampling. An oral-glucose-tolerance test was performed at inclusion and gestational week 27-30.Results: Forty-nine participants completed the study. Thirty-eight participants took >80% of the capsules (n = 21), placebo (n = 17). There was no significant difference in GWG, GDM, HbA1c concentrations, and infant birth weight between groups. Fecal microbiota analyses showed an overall increase in alpha-diversity over time in the probiotic group only (P = 0.016).Conclusions: Administration of probiotics during pregnancy is feasible in obese women and the women were willing to participate in additional study visits and collection of fecal samples during pregnancy. Multistrain probiotic can modulate the gut microbiota in obese women during pregnancy. A larger study population is needed to uncover pregnancy effects after probiotic supplementation.